Can Pharma-Led Expansion Sustain Its Margins and Double-Digit? 

Synopsis: Mold-Tek Packaging is targeting sustained double-digit growth in FY27 through pharma-led expansion, record EBITDA/kg, improved operational efficiencies, and high-margin product diversification, while managing raw material volatility and expanding into medical devices and semiconductor packaging.

The shares of this company are engaged in the manufacturing of injection-molded containers for lubes, pharma, paints, food and other products are in the spotlight after the company reported that pharma revenue is targeted to reach Rs. 50–55 crore in FY27. 

With a market capitalisation of Rs. 2,175 cr, the shares of Mold-Tek Packaging Ltd closed at Rs. 654.75 per share, down from its previous close of Rs. 658.35 per share.  

Strong Financial & Margin Performance

The company delivered a standout performance, with quarterly turnover crossing ~Rs. 300 crore, partially boosted by passing on higher raw material costs. Operating profitability improved significantly, with EBITDA rising to Rs. 46.7/kg, surpassing its historic peak of Rs. 40–42/kg. 

Full-year EBITDA guidance has been revised upward from Rs. 42–43/kg to Rs. 44–45/kg, alongside an overall volume growth target of 10–12% and projected EBITDA growth of 18–20%.

The structural step-up in margins was driven by higher-realisation product mix (+Rs. 3/kg from FMCG and pharma), footprint consolidation, and operational efficiencies (+Rs. 3/kg), alongside modest inventory gains (Rs. 1–1.5/kg). 

A major driver of efficiency was the consolidation of five Hyderabad units into just two units, which significantly lowered overheads, reduced inter-unit transfers, and minimised printing rejection rates.

Segment Dynamics & Growth Strategy

Consolidated volume growth stood at ~6%, slightly muted by a 17% decline in Lubes (which accounts for 17–20% of sales) due to Middle East supply disruptions affecting base oil availability for key clients. 

Paint volumes grew by 10.8%, while Food/FMCG/Thinwall grew by ~24.2%. Moving forward, the company expects Paint to grow at 8–10% CAGR (downward contribution to ~40% over 2–4 years), Food & FMCG at 18–20% CAGR (currently ~24% of revenue), and Pharma at 40–50% CAGR.

Pharma & High-Margin Expansion Roadmap

Pharma revenue is targeted to reach Rs. 50–55 crore in FY27 (up from Rs. 34 crore last year), with run-rates expected to increase from Rs. 11–12 crore/quarter to Rs. 14–15 crore/quarter by year-end. 

Commercialisation of ophthalmic molds is expected early next calendar year supported by a new 25,000 sq ft facility. Additionally, Mold-Tek is targeting medical dosing pens with an initial capacity of 1 million pens/month requiring a 25–30 crore capex (for a 50–60k sq ft setup), and is exploring semiconductor packaging with potential economics of Rs. 150–200/unit or kg.

Capital Expenditure & Cost Dynamics

Overall FY27 capex is expected to moderate to ~Rs. 90 crore (down from Rs. 130–135 crore previously), with ~Rs. 20–22 crore already spent in Q1 and Rs. 25–30 crore allocated to pharma expansion. 

Total capacity stands at ~67,000 MTPA, with plans to add 10–12% incremental capacity annually while driving utilization from ~75% toward 78–80%. Working capital expanded to ~Rs. 125 crore (up from ~Rs. 110–112 crore at FY26 end) due to rising resin prices, which spiked from ~Rs. 107 to a peak of ~Rs. 155 before settling around Rs. 145–146/kg.

In conclusion, Mold-Tek Packaging appears well-positioned to sustain its growth momentum in FY27, supported by record margins, a favorable shift toward high-value pharma and FMCG packaging, and continued operational efficiencies. 

While raw material volatility and weakness in the lubricants segment remain near-term challenges, successful execution of its pharma, medical devices, and semiconductor packaging initiatives will be key to sustaining double-digit growth and elevated margins.

Mold-Tek Packaging Ltd is one of India’s leading manufacturers of rigid plastic packaging solutions. The company caters to industries such as paints, lubricants, food & FMCG, pharmaceuticals, and specialty chemicals, with a strong focus on in-mold labeling (IML) technology and value-added packaging products. It is also expanding into high-growth segments such as medical devices and semiconductor packaging. 

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.